Physician profile
Michael H Hakim
NPI 1225090830
$4,044.49
in general payments reported to CMS, 2019-2025
30 companies · $888 in 2025
The $888 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $222 · 2021: $23.76 · 2022: $60.07 · 2023: $731 · 2024: $720 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.18 |
| Education | $225.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $476.23 | 2019-2024 | |
| Glaxosmithkline, LLC. | $426.29 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $391.43 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $357.84 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $322.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $280.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $278.60 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $208.76 | 2019-2025 | Veozah |
| Vanda Pharmaceuticals INC. | $171.62 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.97 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $119.48 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $110.94 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $95.46 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $86.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $86.76 | 2019-2024 | Eliquis, Camzyos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.25 | 2019-2023 | Xifaxan |
| Exact Sciences Corporation | $66.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $62.90 | 2019 | |
| Merck Sharp & Dohme LLC | $48.06 | 2019 | |
| Corium, LLC | $41.04 | 2023-2024 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $27.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.42 | 2019 | |
| Lundbeck LLC | $17.95 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $17.89 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $17.89 | 2019 | |
| Shield Therapeutics INC | $17.58 | 2023 | Accrufer |
| Antares Pharma, INC. | $17.22 | 2024 | Xyosted |
| Genzyme Corporation | $16.53 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.22 | 2019 | |
| Mylan Specialty L.P. | $15.69 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.